Following the announcement last month that it had fully enrolled its pilot FDA chronic migraine study electroCore has announced that its European randomized controlled trial, GC - 002, for the prevention and acute treatment of chronic cluster headache has been found by the external statistical team to require no changes based on the planned interim sizing analysis. This study, which is a multicentre trial with sites in Germany -5, UK -3, Belgium -1, Italy -1, has as its primary outcome the reduction in the number of cluster headache attacks per week...
No comments:
Post a Comment